The Delhi High Court’s decision comes weeks after the ITC issued an order barring Ultrahuman from selling its smart ring in the American market, where Oura currently dominates
The Delhi High Court has dismissed Ultrahuman’s patent infringement lawsuit against Oura Health, marking a setback in the wearable startup’s battle with the Finnish smart ring maker.
In a Sept. 1 order, Justice Manmeet Pritam Singh Arora found Ultrahuman had “wilful and deliberate” non-disclosure of two recent rulings from the U.S. International Trade Commission (ITC) that barred its smart rings from the American market. The order leaves Ultrahuman liberty to refile, provided it discloses the U.S. rulings and explains their relevance.
In a statement to Athletech News, an Ultrahuman spokesperson said the Delhi High Court had asked the company to refile its complaint because of a procedural clarification.
“This case was filed to defend Ultrahuman’s intellectual property in India,” the spokesperson said. “In our complaint, we included the facts on the ongoing ITC case. However, the court has asked us to include further details and clarifications.”
The spokesperson added that Ultrahuman plans to address the timing of the ITC’s final ruling.
“The ITC Final Determination was released after we filed the DHC case, and the court would like us to add more detail and clarify why it is not relevant to the case (it is not relevant because the patents and the jurisdictions are not related),” the spokesperson said.
The case, filed last month, centered on Ultrahuman’s claim that Oura’s Ring 4 infringed on an Indian patent covering the Ultrahuman Ring Air’s integration of sensors and processing used to deliver sleep and recovery insights. At the time, Ultrahuman accused Oura of copying women’s health tools, circadian health features and glucose monitoring capabilities.
Oura, in response, dismissed the Delhi action as an effort to distract from Ultrahuman’s U.S. loss, where the ITC barred the Ring Air from the American market after finding it infringed on Oura’s intellectual property.
The Delhi High Court ruling follows a recent update Ultrahuman shared with its U.S. customers. In an August 28 blog post titled “Ultrahuman is here for long,” the wearable tech company told Ring Air owners that they will continue to receive subscription-free health insights, regular feature updates and full warranty support.
The company noted that the device will remain on sale in the U.S. through October 21, 2025, but after that date, it “might not be able to sell the Ring Air directly in the U.S.” However, Ultrahuman said retailers and Amazon may continue selling their existing inventory beyond October 21.
The company confirmed a next-generation Ultrahuman Ring is already in development and expects production to begin this December.
“We’re working on clarity around U.S. manufacturing after the ITC review,” Ultrahuman stated. “Once that’s settled, our Texas factory could cover most of the U.S. demand — up to 80%.”
This article has been updated to include a comment from Ultrahuman.
